Cargando…

Novel systemic therapies in the management of tyrosine kinase inhibitor-pretreated patients with epidermal growth factor receptor-mutant non-small-cell lung cancer

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard first-line option for non-small-cell lung cancer (NSCLC) harboring active EGFR mutations. The overall survival of patients with advanced NSCLC has improved dramatically with the development of comprehensive gene...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yang-Si, Jie, Guang-Ling, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475243/
https://www.ncbi.nlm.nih.gov/pubmed/37667782
http://dx.doi.org/10.1177/17588359231193726
_version_ 1785100682562371584
author Li, Yang-Si
Jie, Guang-Ling
Wu, Yi-Long
author_facet Li, Yang-Si
Jie, Guang-Ling
Wu, Yi-Long
author_sort Li, Yang-Si
collection PubMed
description Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard first-line option for non-small-cell lung cancer (NSCLC) harboring active EGFR mutations. The overall survival of patients with advanced NSCLC has improved dramatically with the development of comprehensive genetic profiles and targeted therapies. However, resistance inevitably occurs, leading to disease progression after approximately 10–18 months of EGFR-TKI treatment. Platinum-based chemotherapy is the standard treatment for patients who have experienced disease progression while undergoing EGFR-TKI treatment, but its efficacy is limited. The management of extensively pretreated patients with EGFR-mutant NSCLC is becoming increasingly concerning. New agents have shown encouraging efficacy in clinical trials for this patient population, including fourth-generation EGFR-TKIs, EGFR-TKIs combined with counterpart targeted drugs, and novel agents such as antibody–drug conjugates. We review current efforts to manage extensively pretreated patients with EGFR-mutant NSCLC.
format Online
Article
Text
id pubmed-10475243
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-104752432023-09-04 Novel systemic therapies in the management of tyrosine kinase inhibitor-pretreated patients with epidermal growth factor receptor-mutant non-small-cell lung cancer Li, Yang-Si Jie, Guang-Ling Wu, Yi-Long Ther Adv Med Oncol Review Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard first-line option for non-small-cell lung cancer (NSCLC) harboring active EGFR mutations. The overall survival of patients with advanced NSCLC has improved dramatically with the development of comprehensive genetic profiles and targeted therapies. However, resistance inevitably occurs, leading to disease progression after approximately 10–18 months of EGFR-TKI treatment. Platinum-based chemotherapy is the standard treatment for patients who have experienced disease progression while undergoing EGFR-TKI treatment, but its efficacy is limited. The management of extensively pretreated patients with EGFR-mutant NSCLC is becoming increasingly concerning. New agents have shown encouraging efficacy in clinical trials for this patient population, including fourth-generation EGFR-TKIs, EGFR-TKIs combined with counterpart targeted drugs, and novel agents such as antibody–drug conjugates. We review current efforts to manage extensively pretreated patients with EGFR-mutant NSCLC. SAGE Publications 2023-08-31 /pmc/articles/PMC10475243/ /pubmed/37667782 http://dx.doi.org/10.1177/17588359231193726 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Li, Yang-Si
Jie, Guang-Ling
Wu, Yi-Long
Novel systemic therapies in the management of tyrosine kinase inhibitor-pretreated patients with epidermal growth factor receptor-mutant non-small-cell lung cancer
title Novel systemic therapies in the management of tyrosine kinase inhibitor-pretreated patients with epidermal growth factor receptor-mutant non-small-cell lung cancer
title_full Novel systemic therapies in the management of tyrosine kinase inhibitor-pretreated patients with epidermal growth factor receptor-mutant non-small-cell lung cancer
title_fullStr Novel systemic therapies in the management of tyrosine kinase inhibitor-pretreated patients with epidermal growth factor receptor-mutant non-small-cell lung cancer
title_full_unstemmed Novel systemic therapies in the management of tyrosine kinase inhibitor-pretreated patients with epidermal growth factor receptor-mutant non-small-cell lung cancer
title_short Novel systemic therapies in the management of tyrosine kinase inhibitor-pretreated patients with epidermal growth factor receptor-mutant non-small-cell lung cancer
title_sort novel systemic therapies in the management of tyrosine kinase inhibitor-pretreated patients with epidermal growth factor receptor-mutant non-small-cell lung cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475243/
https://www.ncbi.nlm.nih.gov/pubmed/37667782
http://dx.doi.org/10.1177/17588359231193726
work_keys_str_mv AT liyangsi novelsystemictherapiesinthemanagementoftyrosinekinaseinhibitorpretreatedpatientswithepidermalgrowthfactorreceptormutantnonsmallcelllungcancer
AT jieguangling novelsystemictherapiesinthemanagementoftyrosinekinaseinhibitorpretreatedpatientswithepidermalgrowthfactorreceptormutantnonsmallcelllungcancer
AT wuyilong novelsystemictherapiesinthemanagementoftyrosinekinaseinhibitorpretreatedpatientswithepidermalgrowthfactorreceptormutantnonsmallcelllungcancer